ArticleBMC infectious diseases2025
Epidemiological analysis of pediatric respiratory pathogens in Hunan, China: a retrospective multicenter study from 2022 to 2024.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Epidemiology, bacterial coinfection risk factors, and inflammatory markers in children with RSV, AdV, and hMPV pneumonia in Zunyi, China.BMC infectious diseases · 2026Article
- Pathogen profiles and co-detection characteristics of acute respiratory infections based on active surveillance in a large district of southern China.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Funding
Abstract
backgroundThe zero-COVID policy and non-pharmaceutical interventions (NPIs) implemented in response to COVID-19 concurrently influenced the transmission of other respiratory pathogens. In the post-pandemic era following the policy's cessation, whether the epidemiological patterns of these respiratory pathogens have reverted to pre-pandemic baselines or persisted unchanged remains a subject of interest.
methodsThe retrospective study analyzed 8,774 cases with acute respiratory tract infections (ARTIs) from 2022 to 2024, with data sourced from 26 children's hospitals or general hospitals in Hunan Province, to investigate the potential impacts of policy changes on epidemiology. Nine common respiratory pathogens were detected using targeted next-generation sequencing (tNGS) technology.
resultsAmong children seeking medical care, the overall pathogen positive rate increased (P < 0.001) in both 2023 and 2024, primarily affecting children aged ≤ 1 year and those ≥ 6 years. The positivity rate of respiratory syncytial virus (RSV, both RSV-A and RSV-B) in children aged ≤ 3 years increased and resumed its winter-spring seasonality in 2023-2024, with RSV-A predominant in 2023 and RSV-B in 2024. Human metapneumovirus (HMPV) showing a counter-seasonal pattern. The seasonal epidemics of human parainfluenza virus (HPIV) (mainly HPIV-3) and human bocavirus (HBoV) occur earlier in summer. Influenza A virus (FluA) established typical circulation pattern with influenza B virus (FluB) in autumn and winter. The positive rate of single infection and co-infection of pathogens increased (P < 0.01). The negative co-occurrence patterns between viruses are common. The restricted cubic spline (RCS) model indicates that the susceptible populations for RSV, HMPV, HPIV, and FluA have changed.
conclusionWith the end of the Zero-COVID policy, some respiratory pathogens, including RSV, HPIV, HBoV, and Flu, show clear seasonality. Clinics should closely monitor the epidemiological trends of pediatric respiratory pathogens in the post-pandemic period. CLINICAL TRIAL NUMBER: Not applicable. This study is a retrospective analysis based on clinical data. Since it only involves statistical analysis and no clinical trials, a clinical trial number is not required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.